Mild cognitive impairment (MCI) trials show that disease-modifying treatments can slow cognitive decline by 27 to 35 percent, with two FDA-approved medications now available for early Alzheimer’s disease. The clinical trial landscape for MCI has expanded substantially: as of 2026, 192 clinical trials and 158 novel agents are in development across all disease stages, with 39 percent of Phase 1 trials specifically enrolling MCI participants. This represents a significant shift in how researchers approach early cognitive decline—moving away from waiting until symptoms become severe toward intervening when the brain pathology is still manageable.
The research emerging from these trials tells a more nuanced story than headlines often suggest. Two monoclonal antibody treatments have demonstrated measurable benefits, slowing the progression of cognitive decline over an 18-month period. But alongside pharmaceutical development, researchers are testing non-drug interventions—cognitive training, virtual reality, transcranial magnetic stimulation, and even gene therapy approaches. The trials reveal both genuine promise and important limitations worth understanding if you or a family member is considering enrollment or weighing treatment options.
Table of Contents
- How Many MCI Trials Are Currently Underway, and What Are They Testing?
- What Do FDA-Approved MCI Drugs Actually Show in Clinical Trials?
- What Other Drug Approaches Are Being Tested for MCI?
- What Non-Drug Treatments Are MCI Trials Testing?
- What Are the Real Limitations of Current MCI Trial Data?
- How Do MCI Trials Progress Through Different Research Phases?
- Who Is Currently Eligible for MCI Clinical Trials, and What Does the Population Look Like?
How Many MCI Trials Are Currently Underway, and What Are They Testing?
The scale of MCI research has grown substantially since 2025. The Alzheimer’s drug development pipeline includes 45 treatments in 49 Phase 1 trials, 84 treatments in 89 Phase 2 trials, and 36 potential treatments in 54 Phase 3 trials. Of those Phase 1 trials, 19 out of 49 (39 percent) specifically include MCI participants, meaning nearly four out of every ten early-stage experiments involve people with mild cognitive impairment rather than moderate or severe dementia. This concentration reflects a deliberate research strategy: if a drug can slow decline when the disease is still in its earliest symptomatic stage, it may have a better chance of preventing or delaying progression to dementia.
The types of drugs in these trials fall into three categories: 73 percent are disease-targeting therapies that attempt to alter the underlying pathology (primarily amyloid and tau proteins in Alzheimer’s disease), 18 percent are symptom-targeted therapies designed to enhance cognition or memory, and 10 percent address neuropsychiatric symptoms like depression or anxiety that often accompany cognitive decline. This distribution shows where the research money and effort are concentrated. Disease-targeting therapies dominate because they aim at root causes, not just masking symptoms. However, this also means the average trial participant is part of a larger experiment in mechanism rather than immediate symptom relief.
What Do FDA-Approved MCI Drugs Actually Show in Clinical Trials?
Two monoclonal antibody treatments have now earned FDA approval for MCI due to Alzheimer’s disease, and their trial data reveals both their benefits and their realistic scope. Lecanemab (Leqembi®), approved on January 6, 2023, slowed cognitive decline by 27 percent over 18 months in the CLARITY AD trial, which enrolled approximately 1,800 participants. That sounds significant—and it is—but it translates to a few months of slowed progression. A patient whose decline would normally render them moderately demented within two years might remain in the MCI stage for an additional month or two. It is not a cure or even a major halting of disease; it is a modest slowing. Donanemab (Kisunla™), approved on July 2, 2024, showed stronger results in trial data: approximately 35 percent slower disease progression over 18 months, corresponding to a 4.5- to 7.5-month delay in clinical decline.
This represents a larger effect than lecanemab, though both drugs come with the burden of monthly or bimonthly infusions and the need for amyloid positron-emission tomography (PET) imaging to confirm that brain amyloid pathology is actually present. Not every person diagnosed with MCI has Alzheimer’s pathology—some may have other causes of cognitive decline—so the imaging requirement is not merely procedural; it is clinically necessary. The critical limitation of both drugs is that they are disease-slowing, not disease-stopping. The CLARITY AD trial measured decline on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB), a 18-point scale where lower scores indicate better cognition. Lecanemab-treated participants declined 0.45 points per year versus 0.61 points per year for placebo—a difference that accumulates slowly over years. Neither drug reversed cognitive decline in anyone; they lengthened the amount of time before the decline became more severe.
What Other Drug Approaches Are Being Tested for MCI?
Beyond the two FDA-approved monoclonal antibodies, trials are testing drugs targeting different stages of pathological cascades. Some drugs target amyloid precursor protein or its processing; others target tau phosphorylation or tau aggregation. Still others address inflammation, the glial cell response, or blood-brain barrier integrity. The diversity of mechanisms reflects genuine scientific uncertainty about which pathway offers the best therapeutic window in MCI. One significant class of agents being tested includes tau-targeting therapies. While lecanemab and donanemab focus on amyloid burden, tau protein tangles develop over a longer span and may be the more direct driver of neurodegeneration in individual neurons.
Several Phase 2 and Phase 3 trials are currently evaluating tau immunotherapies and small-molecule tau inhibitors in MCI populations. The theoretical advantage is that tau-targeting might arrest neuronal death more directly, but these trials are still ongoing, and no tau-targeting monoclonal antibody has yet earned FDA approval. Gene therapy approaches are also under investigation. One trial is examining Brain-Derived Neurotrophic Factor (BDNF) gene therapy delivered directly to the brain, with the goal of enhancing neuronal survival and plasticity. This represents a fundamentally different category of intervention—not removing pathological proteins but bolstering the brain’s own protective mechanisms. These trials are typically very small (often fewer than 20 participants) and highly experimental, but they exist because the conventional pharmaceutical approaches, though improving, have not halted MCI progression in any individual so far.
What Non-Drug Treatments Are MCI Trials Testing?
Alongside pharmaceutical development, researchers have designed trials of non-drug interventions targeting cognitive decline. Cognitive training—structured exercises focused on memory, attention, executive function, or processing speed—consistently improved performance on trained tasks and, in some trials, showed transfer to untrained cognitive domains. One challenge is that benefits often fade after training ends; maintaining cognitive gains typically requires ongoing engagement. Some MCI trials are now pairing cognitive training with other interventions (such as physical exercise or sleep optimization) to see if combined approaches produce more durable improvements. Transcranial magnetic stimulation (TMS) is being tested as a stand-alone intervention and in combination with physical exercise.
Early MCI trials found that repetitive TMS applied to regions involved in memory encoding, when paired with an exercise regimen, produced measurable improvements in both cognitive performance and regional brain activation (measured by fMRI). The limitation is that these studies are small and conducted in specialized research settings; scaling TMS to community clinics has proven challenging, and its long-term efficacy beyond the study period remains unclear. Digital and virtual reality interventions represent a newer frontier. Navigation games—immersive 3D environments where participants move through spaces and locate objects—are being tested for their ability to engage spatial memory and spatial navigation circuits, which decline early in Alzheimer’s disease. Virtual reality–based physical and cognitive activity interventions combine balance training, walking challenges, and cognitive tasks in interactive environments. These have shown promise in pilot trials because they increase engagement and provide real-time feedback, but they require specialized equipment and trained supervision, limiting their immediate applicability for most MCI patients.
What Are the Real Limitations of Current MCI Trial Data?
A major limitation of even the best-performing MCI trials is that outcomes are measured on cognitive scales, not on real-world function or quality of life in most cases. The CLARITY AD trial measured the CDR-SB, which is a clinician-administered cognitive and functional assessment, but real-world functional benefits—such as continuing to manage finances, prepare meals, or live independently without assistance—are often not the primary trial endpoints. One person might show a 0.2-point improvement on a cognitive scale but still experience meaningful decline in daily activities; another might remain stable on paper but report subjective worry or behavioral changes not captured by standard measures. Recruitment into MCI trials is heavily skewed toward educated, older adults who are health-conscious and cognitively intact enough to consent and understand study procedures. This means trial populations do not represent the full demographic diversity of people developing MCI, particularly in lower-income communities, racial and ethnic minorities, and those with less education—populations at higher risk for cognitive decline but underrepresented in trials.
The result is that the efficacy and tolerability data reflect a specific demographic, and extrapolating results to different populations carries uncertainty. Another critical limitation is that most MCI trials enroll only people with amyloid-positive MCI—that is, people with documented Alzheimer’s pathology. The broader population of people with MCI is more heterogeneous. Some have tau-predominant pathology, some have vascular cognitive impairment, some have Lewy body disease, and some have mixed etiologies. Drugs that slow amyloid-related decline may have minimal effect in a person whose MCI is driven by another mechanism. The trial data thus applies most directly to the amyloid-positive subset, not to all people with cognitive impairment.
How Do MCI Trials Progress Through Different Research Phases?
Clinical trials follow a standardized progression from Phase 1 (safety and dosage in small groups, typically 20–100 participants) through Phase 2 (efficacy and side effects in a larger group, typically 100–500 participants) and Phase 3 (efficacy confirmation and adverse reaction monitoring in large populations, typically 1,000–5,000 participants) to potential FDA review and approval. For MCI trials, Phase 1 typically lasts 6–12 months; Phase 2 typically lasts 6–24 months; and Phase 3 often lasts 18–36 months because cognitive changes accumulate slowly and long follow-up is needed to detect meaningful differences. As of 2026, eight Phase 3 trials are expected to reach their primary completion date, and 29 Phase 2 trials are projected to complete in 2026.
The progression through phases is not automatic. If a Phase 2 trial fails to show evidence of efficacy or reveals unexpected safety concerns, the drug does not advance to Phase 3, and further development may halt. Conversely, if a Phase 3 trial succeeds, the sponsor may submit the data to the FDA for approval, which, as with lecanemab and donanemab, can happen on an accelerated timeline if the data are compelling and the unmet medical need is high. Between trial phases, there are often refinements in dosage, administration route, or study population based on earlier results.
Who Is Currently Eligible for MCI Clinical Trials, and What Does the Population Look Like?
As of 2026, the estimated population of people with MCI who have AD pathology is 2.43 million, a number projected to reach 5.7 million in coming years. These are people typically in their 60s, 70s, or 80s with measurable cognitive decline—often noticeable to themselves and family members—but without the severe functional impairment that defines dementia. They may have difficulty remembering recent conversations, managing complex financial tasks, or organizing a multistep activity, yet they can still live independently and manage basic self-care.
Trials recruiting MCI participants typically require: objective evidence of cognitive impairment (usually a score in a specific range on cognitive tests like the Montreal Cognitive Assessment), confirmation of Alzheimer’s pathology via biomarkers (amyloid PET imaging or cerebrospinal fluid testing, or more recently, blood biomarkers like phosphorylated tau), normal or near-normal basic activities of daily living, absence of dementia, and often age criteria (such as 50 or older). Some trials exclude people with significant comorbid conditions like uncontrolled hypertension or diabetes, active depression, or other neurological conditions. These inclusion and exclusion criteria ensure a somewhat homogeneous study population but also limit how representative trial participants are of the broader population of people experiencing cognitive decline in real-world settings. A person with MCI and well-controlled diabetes, mild depression, or a prior stroke might be excluded from a major trial, yet these comorbidities are common in actual MCI populations.
- —
